• Home

  • HEALTH CARE

  • HEALTHY LIFESTYLE

  • HYGIENE

  • COSMETICS

  • FOR HIM

  • PREGNANCY AND MOTHERHOOD

  • CHILD

    2. HEALTH CARE
    3. Coraxan 5mg 56 tablets — Made in Ireland — Free Delivery

    Coraxan 5mg 56 tablets — Made in Ireland — Free Delivery


    Brand: Servier
    Product Code: Coraxan 5mg
    Availability: In Stock
    $39.65
    Add to Cart

    Pharmachologic effect

    Antianginal preparation. The mechanism of action consists in selective and specific inhibition of the If channels of the sinus node, which control spontaneous diastolic depolarization in the sinus node and regulate heart rate.
    The main pharmacological feature of ivabradine is its ability to dose-dependently reduce heart rate. The analysis of the dependence of the magnitude of the decrease in heart rate on the dose of the preparation was carried out with a gradual increase in the dose of ivabradine to 20 mg 2 times / day. and revealed a tendency to achieve a plateau effect (no increase in the therapeutic effect), which reduces the risk of developing severe, poorly tolerated bradycardia (heart rate less than 40 beats / min).
    When the preparation is prescribed in recommended doses, the decrease in heart rate is approximately 10 beats / min at rest and during exercise. As a result, the work of the heart decreases and the demand for oxygen in the myocardium decreases.
    A sustained decrease in heart rate was demonstrated in patients taking ivabradine for at least 1 year (n = 713). No effect on glucose or lipid metabolism was observed.
    In patients with diabetes mellitus (n = 457), ivabradine demonstrates efficacy and safety, as in other, comparable in number, patient groups.

    Indications

    Stable angina: symptomatic therapy of stable angina in IHD in adult patients with normal sinus rhythm and heart rate of at least 70 beats / min:
    with intolerance or contraindications to the use of beta-blockers;
    in combination with beta-blockers with inadequate control of stable angina pectoris against the background of the optimal dose of beta-blocker.
    Chronic heart failure:
    therapy of chronic heart failure II-IV class according to NYHA classification with systolic dysfunction in patients with sinus rhythm and heart rate of at least 70 bpm in combination with standard therapy, including therapy with beta-blockers, or in case of intolerance or contraindications to use beta-blockers.

    Method of administration and dosage

    Coraxan should be taken orally 2 times / day, in the morning and in the evening during meals. The dosage and duration of admission is determined by the doctor.

    Contraindications

    Resting heart rate below 60 beats / min (before treatment);
    • cardiogenic shock;
    • acute myocardial infarction;
    • severe arterial hypotension (systolic blood pressure below 90 mm Hg and diastolic blood pressure below 50 mm Hg);
    • severe liver failure (more than 9 points on the Child-Pugh scale);
    • SSSU;
    • sinoatrial blockade;
    • chronic heart failure of the III and IV functional class according to the NYHA classification (due to the lack of sufficient clinical data);
    • the presence of an artificial pacemaker;
    • unstable angina;
    • AV block III degree;
    • simultaneous use with strong inhibitors of CYP3A4, such as antifungal agents of the azole group (ketoconazole, itraconazole), antibiotics from the macrolide group (clarithromycin, oral erythromycin, josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and nefazodonavir; and nefinavir;
    • hypersensitivity to ivabradine or any component of the preparation.

    Special instructions

    Coraxan is not effective for the treatment or prevention of cardiac arrhythmias. Its effectiveness decreases against the background of the development of tachyarrhythmias (for example, ventricular or supraventricular tachycardia).
    The use of Coraxan in conjunction with calcium channel blockers that slow down the heart rate (verapamil or diltiazem) is not recommended.
    The preparation contains lactose, therefore, Coraxan is not recommended for patients with lactose intolerance, lactase deficiency or impaired absorption of glucose and galactose.
    With the use of grapefruit juice against the background of the use of Coraxan, an increase in the concentration of ivabradine in the blood was noted by 2 times. During the period of ivabradine therapy, the intake of grapefruit juice and St. John's wort preparations should be minimized.
    It has been shown that, in general, the use of Coraxan does not affect the ability to drive, but due to the possibility of photopsy, the patient should be careful when engaging in potentially hazardous activities that require a high speed of psychomotor reactions.

    Storage conditions

    The preparation should be kept out of the reach of children. No special storage conditions are required.

    There are no reviews for this product.
    VEV Healthcare Store © 2017